Calcineurin inhibitors revisited: A new paradigm for COVID-19?

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than a direct viral damage disease. Therapies for COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Hage, René, Steinack, Carolin, Schuurmans, Macé M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320855/
https://www.ncbi.nlm.nih.gov/pubmed/32603679
http://dx.doi.org/10.1016/j.bjid.2020.06.005
_version_ 1783551330849128448
author Hage, René
Steinack, Carolin
Schuurmans, Macé M.
author_facet Hage, René
Steinack, Carolin
Schuurmans, Macé M.
author_sort Hage, René
collection PubMed
description The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than a direct viral damage disease. Therapies for COVID-19 are all investigational therapies. In case of severe disease, treatment with a calcineurin inhibitor could be promising. In this article we explain the mechanisms of calcineurin inhibitor treatment for COVID-19, based on experiences seen in solid organ transplant recipients who suffered from COVID-19.
format Online
Article
Text
id pubmed-7320855
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-73208552020-06-29 Calcineurin inhibitors revisited: A new paradigm for COVID-19? Hage, René Steinack, Carolin Schuurmans, Macé M. Braz J Infect Dis Brief Communication The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than a direct viral damage disease. Therapies for COVID-19 are all investigational therapies. In case of severe disease, treatment with a calcineurin inhibitor could be promising. In this article we explain the mechanisms of calcineurin inhibitor treatment for COVID-19, based on experiences seen in solid organ transplant recipients who suffered from COVID-19. Elsevier 2020-06-27 /pmc/articles/PMC7320855/ /pubmed/32603679 http://dx.doi.org/10.1016/j.bjid.2020.06.005 Text en © 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Communication
Hage, René
Steinack, Carolin
Schuurmans, Macé M.
Calcineurin inhibitors revisited: A new paradigm for COVID-19?
title Calcineurin inhibitors revisited: A new paradigm for COVID-19?
title_full Calcineurin inhibitors revisited: A new paradigm for COVID-19?
title_fullStr Calcineurin inhibitors revisited: A new paradigm for COVID-19?
title_full_unstemmed Calcineurin inhibitors revisited: A new paradigm for COVID-19?
title_short Calcineurin inhibitors revisited: A new paradigm for COVID-19?
title_sort calcineurin inhibitors revisited: a new paradigm for covid-19?
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320855/
https://www.ncbi.nlm.nih.gov/pubmed/32603679
http://dx.doi.org/10.1016/j.bjid.2020.06.005
work_keys_str_mv AT hagerene calcineurininhibitorsrevisitedanewparadigmforcovid19
AT steinackcarolin calcineurininhibitorsrevisitedanewparadigmforcovid19
AT schuurmansmacem calcineurininhibitorsrevisitedanewparadigmforcovid19

Ejemplares similares